Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

IVBIY

IVBIY
Current price
22 USD 0 USD (0.00%)
Last closed 22 USD
Company
ISIN unknown
Sector Healthcare
Industry Biotechnology
Exchange PINK
Capitalization 8 932 307 968 USD
Yield for 12 month +69.23 %
1Y
3Y
5Y
10Y
15Y
IVBIY
21.11.2021 - 28.11.2021

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China. Address: 168 Dongping Street, Suzhou, China, 215123

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

P/E ratio

Dividend Yield

Current Year

+875 463 048 USD

Last Year

+642 748 522 USD

Current Quarter

Last Quarter

Current Year

+715 174 992 USD

Last Year

+511 417 850 USD

Current Quarter

Last Quarter

Key Figures IVBIY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -1 344 642 560 USD
Operating Margin TTM -18.74 %
PE Ratio
Return On Assets TTM -5.19 %
PEG Ratio
Return On Equity TTM -11.04 %
Wall Street Target Price
Revenue TTM 7 456 828 928 USD
Book Value 7.66 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 46.3 %
Dividend Yield
Gross Profit TTM
Earnings per share -0.46 USD
Diluted Eps TTM -0.46 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -17.18 %

Dividend Analytics IVBIY

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IVBIY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IVBIY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 7.6998
Price Sales TTM 1.2038
Enterprise Value EBITDA -6.445
Price Book MRQ 5.0714

Financials IVBIY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators IVBIY

For 52 weeks

13 USD 24.14 USD
50 Day MA 20.32 USD
Shares Short Prior Month
200 Day MA 20.16 USD
Short Ratio
Shares Short
Short Percent

Dynamics of changes in the value of assets

0

0P8

183.40 EUR Penumbra Inc +0.99 (+0.49%)
Detailed analytics
5

5F6

39.20 EUR SUMITOMO FORESTRY +0.22 (+0.51%)
Detailed analytics
1

1801

43.30 HKD Innovent Biologics Inc +0.21 (+3.84%)
Detailed analytics
NNN

NNN

48.46 USD National Retail Properties Inc +0.23 (+0.48%)
Detailed analytics
S

SSDOY

21.95 USD Shiseido Company Ltd +0.05 (+0.23%)
Detailed analytics